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HIV infection causes loss of CD4 T cells and type 1
interferon (IFN)–producing and IFN-responsive den-
dritic cells, resulting in immunodeficiencies and sus-
ceptibility to opportunistic infections, such as Pneu-
mocystis. Osteoporosis and bone marrow failure are
additional unexplained complications in HIV-positive
patients and patients with AIDS, respectively. We re-
cently demonstrated that mice that lack lymphocytes
and IFN a/b receptor (IFrag/) develop bone mar-
row failure after Pneumocystis lung infection,
whereas lymphocyte-deficient, IFN / receptor–
competent mice (RAG/) had normal hematopoie-
sis. Interestingly, infected IFrag/ mice also exhib-
ited bone fragility, suggesting loss of bone mass. We
quantified bone changes and evaluated the potential
connection between progressing bone fragility and
bone marrow failure after Pneumocystis lung infec-
tion in IFrag/ mice. We found that Pneumocystis
infection accelerated osteoclastogenesis as bone mar-
row failure progressed. This finding was consistent
with induction of osteoclastogenic factors, including
receptor-activated nuclear factor-B ligand and the
proapoptotic factor tumor necrosis factor–related
apoptosis-inducing ligand, in conjunction with their
shared decoy receptor osteoprotegerin, in the bone
marrow of infected IFrag/ mice. Deregulation of
this axis has also been observed in HIV-positive indi-
viduals. Biphosphonate treatment of IFrag/ mice
prevented bone loss and protected loss of hematopoi-
etic precursor cells that maintained activity in vitro
but did not prevent loss of mature neutrophils. To-
gether, these data show that bone loss and bone mar-
row failure are partially linked, which suggests thatthe deregulation of the receptor-activated nuclear fac-
tor-B ligand/osteoprotegerin/tumor necrosis factor–
related apoptosis-inducing ligand axis may connect
the two phenotypes in our model. (Am J Pathol 2012,
181:151–162; http://dx.doi.org/10.1016/j.ajpath.2012.03.023)
HIV infection results in loss of CD4 T cells and dendritic
cells, which include type 1 interferon (IFN)–producing
plasmacytoid dendritic cells.1,2 This process generates a
complex immunodeficiency with susceptibilities to oppor-
tunistic infections and cancer.3 Autoimmune phenom-
ena,4 bone marrow failure,5,6 and osteoporosis can also
occur, but underlying mechanisms are poorly under-
stood. Although the role of CD4 T cells in the prevention
of AIDS progression is undoubted,7,8 the role of type 1
IFNs is controversially discussed. Type 1 IFNs are proin-
flammatory and antiviral9 but are also important immune
modulators.10 There is clear evidence of an independent,
protective role of type 1 IFNs in the control of viral repli-
cation and protection from opportunistic infection.11–13
However, it is also debated whether type 1 IFN responses
during HIV infection are linked to the excessive immune
activation seen in patients, causing bystander T-cell de-
pletion or dysfunction.14,15 These data point to the impor-
tance of balanced action of mediators to maintain system
homeostasis during inflammatory responses.
Although highly active antiretroviral therapy (HAART)
has greatly reduced the progression to severe immuno-
deficiency and thus death due to opportunistic infections,
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T-cell repertoire and numbers and type 1 IFN-producing
dendritic cells.12,16–18 This incomplete recovery can re-
sult in deviated immune responses. Indeed, the epidemi-
ology of disease manifestations in treated HIV-positive
individuals has changed. Unexplained chronic pulmo-
nary sequelae, such as chronic obstructive pulmonary
disease (COPD)19,20 and accelerated osteoporosis,21–23
now appear at the forefront of disease management.
A close relationship exists between bone metabolism
and inflammation as well as hematopoiesis and inflam-
mation.24,25 All blood cells, and therefore immune cells,
are generated in the bone marrow, in which hematopoi-
etic stem cells reside in unique niches, interacting with
osteoblasts of the bone.26–28 Distinct cytokines relevant
in inflammation, such as IL-1, tumor necrosis factor
(TNF)-, and receptor-activated nuclear factor-B ligand
(RANKL), also regulate bone metabolism by activating
bone-resorbing osteoclasts, which also mobilize hemato-
poietic stem cells from their bony niche. In contrast, other
mediators, such as osteoprotegerin (OPG), IFN-, type 1
IFNs, and IL-4, suppress osteoclast activation.24 Abnor-
mal or chronic immune activation enhances osteoclasto-
genic cytokine activity and can result in focal bone destruc-
tion and accelerated bone loss because it occurs in
rheumatoid arthritis and other inflammatory diseases.29,30
In this regard, chronic inflammatory lung diseases, such
as COPD, are also consistently associated with acceler-
ated osteoporosis as a systemic manifestation of the dis-
ease, although the triggering mechanisms are not clear.31
Interestingly, severe osteoporosis in these chronic lung
diseases is also associated with anemia and reduced
circulating bone marrow progenitor cells.32 This finding
demonstrates that focal diseases can have an unex-
pected systemic effect on other organ systems, such as
the bone and bone marrow.
The prevalence rate of osteoporosis resulting in in-
creased fracture risk is more than three times higher in
HIV-positive patients compared with HIV-negative con-
trols.33 The cause of these bone changes is controver-
sial, and treatment with HAART, especially protease in-
hibitors, appears to contribute to the phenotype.21,22
However, patients who have never received antiretroviral
therapy also have an increased incidence of osteoporo-
sis.34 This finding suggests that additional factors, such
as deviated systemic immune activation in response to
opportunistic infections, might contribute. In this regard,
low CD4 T-cell counts are considered a risk factor for
osteoporosis.35 However, the potential contribution of a
deviated systemic immune response to low-grade pulmo-
nary opportunistic infections in accelerating osteoporosis
in the context of a variable defect of the type 1 IFN
system, as can occur in HIV-positive patients, has not
been evaluated.
Pneumocystis is a pulmonary fungal pathogen capable
of causing a severe interstitial pneumonia in patients with
lymphocyte deficiency and/or a defect of the type 1 IFN
system.1,11,12 Pneumocystis is the most common oppor-
tunistic infection in AIDS, although it also affects patients
undergoing chemotherapy, those receiving anti-TNF-
therapy,36–38 or patients with inherited CD4 T-cell de-fects.3 In addition, low-grade Pneumocystis colonization
exacerbates COPD and other chronic pulmonary dis-
ease, not only in HIV-positive patients undergoing
HAART39 but also in patients without known immune de-
fects who are likely undergoing glucocorticoid treat-
ments. However, Pneumocystis colonization and COPD
are significantly higher in HIV-positive patients undergo-
ing HAART compared with HIV-negative individuals.33,34
Interestingly, anti-inflammatory mechanisms of glucocor-
ticoids also impair the type 1 IFN system.40,41
Given the clear association between chronic inflamma-
tory pulmonary disease and osteoporosis and the impli-
cation that Pneumocystis exacerbates such disease, we
questioned whether the systemic response to Pneumo-
cystis infection in the context of a defective type 1 IFN
system might accelerate osteoporosis.
Using a mouse model of Pneumocystis infection, we
recently demonstrated an important role of the type 1 IFN
system in regulating the systemic responses to the infec-
tion.42,43 Pneumocystis lung infection in mice lacking lym-
phocytes and type 1 IFN receptor (IFrag/ mice) results
in rapidly progressing bone marrow failure, characterized
by severe reduction of bone marrow cellularity affecting
all hematopoietic lineages and loss of hematopoietic
stem cell function when tested in hematopoietic colony-
forming assays, despite minimal pathogen burden within
16 days due to accelerated apoptosis of mature and
precursor cells. During progression of bone marrow fail-
ure in IFrag/ mice, we also observed increasingly brit-
tle bone. In contrast, IFN / receptor (IFNAR)–compe-
tent but lymphocyte-deficient RAG/ mice have normal
hematopoiesis and die of Pneumocystis pneumonia with
high pathogen burden after 4 to 5 weeks. Furthermore, no
apparent bone changes were observed in RAG/ mice.
This study aimed to evaluate and quantify the impression
of accelerated bone loss in response to Pneumocystis lung
infection in our mouse model, elucidate mechanisms asso-
ciated with this phenotype, and determine whether a causal
link exists between bone loss and bone marrow failure. Our
data suggest that bone loss in IFrag/mice in response to
Pneumocystis lung infection is caused by inflammation-in-
duced accelerated osteoclastogenesis and that bone loss
and bonemarrow failure are partially linked, possibly involv-
ing deregulation of the RANKL/OPG/TNF-related apoptosis-
inducing ligand (TRAIL) axis.
Materials and Methods
Mice
C.B17 SCID mice, as a source for Pneumocystis murina
organisms, were bred and maintained at Montana State
University (MSU) Animal Resource Center. RAG1/
mice, herein referred to as RAG/ mice (C57/BL6 back-
ground), were initially purchased from Jackson Labora-
tories (stock number 002096) and then bred at MSU.
IFrag/mice were generated by crossing IFNAR knock-
out mice (129SvEv background and maintained at MSU)
with RAG1/ mice (C57/BL6 background), herein re-
ferred to as RAG/mice, as previously described42 and
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ground. Animals were kept in ventilator cages with ster-
ilized food and water. All mouse studies conformed to
NIH guidelines and were approved by the Institutional
Animal Care and Use Committee MSU. Some mice were
treated with risedronate, a bisphosphonate, which in-
hibits osteoclasts to prevent loss of bone mass. For
this, 10 g/kg risedronate (Wako, Tokyo, Japan) was
administered intraperitoneally five times per week.44
For in vivo neutralization of TRAIL, mice were injected
intraperitoneally with 750 g of TRAIL-neutralizing an-
tibody (clone N2B2; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) every other day during the infection,
starting 1 day before the Pneumocystis infection.
Pneumocystis Lung Infection
Pneumocystis was isolated from heavily infected source
mice. Experimental animals were intratracheally infected
with 1  107 Pneumocystis nuclei in 100 L of lung
homogenate from infected source mice diluted in PBS
buffer. Pneumocystis burden of infected animals was as-
sessed microscopically (Zeiss Axiostar microscope;
Zeiss, Jena, Germany) by enumeration of trophozoid nu-
clei count in lung homogenates in 10 to 50 oil immersion
fields as previously described. The limit of detection for
this technique is log10 4.43.
45 A previously established
time course of infection was used in the presented
studies comparing Pneumocystis-infected IFrag/
and RAG/ mice. Bone and bone marrow responses
of infected mice were therefore evaluated at day 0, 7,
10, and 16 after Pneumocystis lung infection. These
groups are herein referred to as day 0, 7, 10, and 16
IFrag/ or RAG/ mice. Each group consisted of
four mice per time point, and each experiment was
repeated at least twice.
Bone Marrow Flushes, Enumeration, and
Differentiation
Bone marrow cells from femur and tibia were collected as
previously described by flushing 2 mL of PBS through the
bone marrow canal using a 26½-g needle and brought
into a single cell suspension.46 Bone marrow cells were
diluted 1:10 in PBS, enumerated, spun onto glass slides,
and stained with Diff-Quick solution (Dade Behring, Deer-
field, IL). Cell differentiation was performed based on
morphologic and staining pattern to distinguish myeloid
(including myeloblast-myelocyte and metamyelocyte
stage), erythroid, neutrophil, and eosinophil cells.46
Osteoclast Activity Assays in Bone Marrow
Lysates and on Tissue Sections
Osteoclast formation was assayed in bone marrow cell
lysates (preosteoclasts) and on bone sections (mature
osteoclasts) from IFrag/ and RAG/mice in response
to Pneumocystis lung infection by detecting osteoclast-
specific tartrate resistant acidic phosphatase (TRAP) ac-
tivity. A soluble TRAP assay was performed in bone mar-row cell lysates as previously described47,48 using a
leukocyte acidic phosphatase kit (386A-1KT; Sigma-Al-
drich, St. Louis, MO). Briefly, total bone marrow cells
were suspended in PBS and adjusted to 6  106 cells/
mL. A 50-L cell suspension was pipetted in duplicate
into round bottom 96-well enzyme-linked immunosorbent
assay (ELISA) plates (Costar, Milpitas, CA). Cells were
pelleted for 30 seconds at 300  g in a Sorval tabletop
centrifuge, the supernatant removed, and cells lysed in
50 L of cold cell lysis buffer containing 90 mmol/L citrate
buffer, pH 5.5, 0.1% Triton X, and 80 mmol/L sodium
tartrate. A total of 50 L of substrate solution [5.4 mmol/L
(2 mg/mL) p-nitrophenyl phosphate (Sigma-Aldrich) dis-
solved in lysis buffer] was added to the lysate, mixed,
and incubated for 1 hour at 37°C in the dark. The reaction
was stopped by adding 50 L of 0.5 mol/L NaOH to each
well, the assay was read at 405 nm using a plate assay
reader, and data were plotted in OD. Positive controls for
the assays were bone marrow cells lysed in the same lysis
buffer but not containing tartrate to assay for all acidic
phosphatases. Negative controls for the assay contained
bone marrow lysates pretreated with NaOH, lysates with no
substrate added, or assay buffer with no lysate added.
For TRAP staining on formalin-fixed and decalcified
bone sections, femur and tibia were placed in 10% ice
cold buffered formalin solutions for 24 hours. Bones were
decalcified in 5% EDTA in PBS, pH 7.4 to 7.6, at 4°C for
approximately 3 to 5 days, rinsed in tap water for 30
minutes, and placed into cold 70% ethanol until further
processing. Paraffin embedded bones were cut in
5-m sections using a Leica RM2255 microtome (Leica
Microsystems, Wetzlar, Germany) and deparaffinized.
Staining was performed using the leukocyte acidic
phosphatase kit from Sigma-Aldrich (St. Louis, MO)
(386A-1KT) following the manufacturer’s protocol, ex-
cept the counterstain was performed using hematoxy-
lin 1 (Richard Allen Scientific, Kalamzoo, MI) including
a bluing and clarifying step.
Histomorphometric Analysis
Comparative histomorphometric analysis of bones from
Pneumocystis-infected IFrag/ and RAG/ mice was
performed by The University of Alabama at Birmingham
Center of Metabolic Bone Diseases Core Laboratory on
excised mouse femurs, fixed in 70% ETOH. Longitudinal
sections (5 m thick) were cut at the 50% plane from
methyl methacrylate embedded blocks using a Leica
2265 microtome. These were stained with Goldner’s
trichrome stain for the static measurements. A region of
interest was selected that is exactly 250 m distal to the
growth plate and extending 1 mm downward (thereby
avoiding the primary spongiosa) through the metaphysis of
the femur. Standard bone histomorphometric analysis was
performed by themethods of Parfitt et al49,50 using Bioquant
Image Analysis software (R & M Biometrics, Nashville,
TN). Four types of primary measurements were
made—area, length (perimeter), distance, and num-
ber. These referents, such as tissue volume, bone vol-
ume, bone surface, and osteoid surface, were used to
154 Wilkison et al
AJP July 2012, Vol. 181, No. 1derive other indices, such as trabecular number and
trabecular separation.
MicroCT for the Evaluation of Bone Architecture
Microcomputed tomography (microCT) analysis was per-
formed to evaluate structural parameters of cancellous
and cortical bone by a nondestructive procedure. Anal-
ysis was performed by Scanco USA Inc. (Wayne, PA).
The individual specimens were transferred into a Scanco
specimen holder and then immersed in 70% ethanol.
Specimens were positioned lengthwise in the specimen
holder to acquire scans at the highest voxel resolution
possible for a specimen holder at that size. All scanning
was conducted on a Scanco microCT 40 scanner. X-ray
energy of 55 Kvp at a current of 145 A was used.
Images were acquired with a field of view of 12.28 mm
and matrix size of 2048  2048 (2000 projections at
360°), resulting in a voxel size of 6 m. Beam-hardening
correction (1200 hardening artifact mg/mL) was used
(standard on Scanco microCT systems). A single-frame
average with an integration time of 300 milliseconds per
projection was used for all scans.
Trabecular Bone Imaging
A total of 550 to 650 sections (covering a distance of 3 to
4 mm) were acquired from the metaphyseal region of the
proximal femur. The raw data were reconstructed (auto-
matically) to image data using the reconstruction soft-
ware bundled with the microCT system (Scanco).
Cortical Bone Imaging
A total of 110 to 120 sections (covering 0.6 to 0.7 mm)
were acquired from the midshaft of the femur. For trabec-
ular bone analysis a region of interest was manually con-
toured to include only the trabecular bone compartment
for a distance of 1.2 mm (200 sections). Images were
filtered using a G filter (  0.8; support  1.0) and were
segmented using a global threshold value of 230. Tra-
becular bone parameters were calculated using the stan-
dard Scanco software suite. A total of 100 sections (cov-
ering a distance of 0.6 mm) were analyzed for cortical
bone parameters. Images were filtered using a G filter
(  0.8; support  1.0) and were segmented using a
global threshold of 350. Cortical bone parameters were
calculated using the standard Scanco software suite.
Cytokine Analysis in Bone Marrow Cell Lysates
Bone marrow cells from day 0, 7, 10, and 16 IFrag/ and
Rag/ mice were isolated, and 5  106 total cells were
lysed in 100 L of cell lysis buffer (Biovision Inc, Milipitas,
CA). Each group consisted of four animals per time point.
Protein assays were performed using bicinchoninic acid
assay reagents (Pierce Protein Research Projects,
Thermo Fisher Scientific Inc, Rockford, IL) to ensure
equal protein concentrations. Twenty-five microliters of
lysate from each mouse was assayed in duplicate for anarray of inflammatory and bone metabolism–related cy-
tokines using multiplex and single-plex bead ELISA kits
from Millipore with subsequent analysis on a Bio-Plex200
system (Bio-Rad Laboratories, Hercules, CA). The follow-
ing analytes were assessed using reagents from Milli-
pore: macrophage colony-stimulating factor (M-CSF),
IL-6, IL-1, IL-, TNF-, RANKL, and OPG. For the de-
tection of the apoptotic factor TRAIL, a sandwich ELISA,
was established using a mouse TRAIL capture and de-
tection antibody pair from R&D Systems following the
manufacturer’s instructions (R&D Systems Duo Set
mouse TRAIL; R&D Systems, Minneapolis, MN). A stan-
dard curve was generated, the assay was read at 450 nm
on a plate reader, and results were analyzed using Soft-
max Pro software (Molecular Devices, Sunnyvale, CA).
CFC Assay for Mouse Bone Marrow Cells
Hematopoietic precursor cell (HPC) activity in bone mar-
row from IFrag/ and RAG/ mice was assessed by
performing colony-forming cell (CFC) assays in methyl-
cellulose media. For these assays, 1  105 bone marrow
cells were plated in MethCult GF M3534 media (StemCell
Technologies, Vancouver, BC), which was formulated to
support the optimal growth of granulocyte and macro-
phage precursor cells. Cells from each sample were
plated in duplicate according to the manufacturer’s pro-
tocol in 35-mm sterile culture dishes (StemCell Technol-
ogies) and placed in 100-mm petri dishes in the pres-
ence of one 35-mm dish that contained sterile water.
Cultures were incubated for 7 days in a water-jacketed
incubator maintained with 5% CO2. Colony recognition
(granulocyte-macrophage–, granulocyte-, and macro-
phage-forming colonies) and enumeration were per-
formed according to the StemCell Technologies guide-
lines.
Statistical Analysis
Statistical analysis was performed using either a one-way
or two-way analysis of variance followed by either a
Tukey or a Bonferroni posttest.
Results
Association of Bone Marrow Failure in IFrag/
Mice with Increased Osteoclast Differentiation
and Activity along the Trabecular Bone in
Response to Pneumocystis Lung Infection
We previously reported that IFrag/ mice develop pro-
gressive bone marrow failure during systemic responses
to Pneumocystis lung infection, whereas hematopoiesis
was unaffected in RAG/ mice.42 In a previously estab-
lished time course (day 0, 7, 10, and 16 after Pneumo-
cystis), we demonstrated that events around day 7 after
Pneumocystis lung infection are critical in determining the
bone marrow response.43 We also show that during this
time course IFN- serum concentrations in RAG/ mice
peak at day 7 after infection (Figure 1A), clearly demon-
OD. Stat
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during Pneumocystis lung infection to which IFrag/
mice are unable to respond.
During the progression of bone marrow failure, IFrag/
mice also appear to develop brittle bone, suggesting loss of
bone mass possibly due to inflammation-induced acceler-
ated osteoclast activity. We wanted to verify this finding,
quantify osteoclast activity, and determine whether the
bone loss is causally related to the development of bone
marrow failure in our system. Therefore, we determined
whether preosteoclast differentiation was enhanced in
bone marrow from IFrag/ but not RAG/ mice after
Pneumocystis lung infection. For this we measured TRAP
activity in bone marrow cell lysates from equal cell num-
bers harvested during the infection as a relative indicator
for pre osteoclast numbers. Figure 1B shows typical bone
marrow cell counts comparing IFrag/ versus RAG/
mice during Pneumocystis lung infection, with bone mar-
row cell numbers decreasing only in IFrag/ mice as an
indicator of bone marrow failure.43 TRAP activity mea-
sured in lysates from these bone marrow cells signifi-
cantly increased in IFrag/ compared with RAG/
mice on day 7 after infection (Figure 1C). However, at day
16 after infection this activity disappeared, suggesting
either death of these precursors or further differentiation
and attachment to the bone.
To determine whether increased preosteoclast differ-
entiation would also result in enhanced accumulation of
Figure 1. Induction of bone marrow failure in IFrag/ mice is associated
mice were determined over time, from day 0 to day 16. B: Bone marrow cell
from day 0, 7, 10, and 16 IFrag/ and RAG/ mice during Pneumocystis lu
not in RAG/ mice. Each group consisted of four animals per time point. C:
cells from each animal and time point. Activity was assayed and plotted in
shown are mean  SEM (n  4). ***P  0.001.mature osteoclasts active along the trabecular bone of
IFrag/ mice, TRAP stains were performed on bone
sections of day 0 (uninfected) and day 16 IFrag/ mice.
Figure 2 shows a representative TRAP stain on decalci-
fied and paraffin-embedded femurs from day 0 (Figure
2A) and day 16 IFrag/ mice (Figure 2B). The oste-
oclasts stained red and were visible along the trabecular
bone, consistently giving the impression that more oste-
oclasts were lining bone structures of infected compared
with uninfected IFrag/ mice. We also noted that the
number and sizes of trabecular bone of infected IFrag/
mice appeared diminished. To quantify this observation
and compare this response to RAG/ mice, bone histo-
morphometric studies were performed on calcified and
plastic-embedded femurs excised from day 0 and day 16
IFrag/ and RAG/ mice. Shown in Figure 3A are von
Kossa stains demonstrating mineralized bone structures.
Goldner’s trichrome stain was used for histomorphomet-
ric analysis [Figure 3B; original magnification: 40 (B);
200 (insets)], and results are summarized in Figure 3,
C-G. For statistical analysis all comparisons were made
to day 0 RAG/ mice. This analysis showed the bone
perimeter per tissue area (Figure 3C) and trabecular
bone numbers (Figure 3D) significantly reduced only in
day 16 IFrag/ mice in response to Pneumocystis lung
infection and no changes in day 16 RAG/ mice. These
data are consistent with loss of bone mass. Also consis-
tent with this finding are an increased number of oste-
reased preosteoclast differentiation. A: Levels of IFN- in serum of RAG/
ere performed microscopically from bone marrow flushes of both hind legs
ctions, demonstrating progressive bone marrow failure in IFrag/ mice but
tivity was measured in bone marrow cell lysates using 3 105 bone marrow
istical analysis was performed using a two-way analysis of variance. Values
Figure 2. Osteoclast numbers increase along
the trabecular bone of IFrag/ mice in re-
sponse to Pneumocystis lung infection. TRAP
staining was performed on formalin-fixed and
paraffin-embedded bone sections from day 0
(A) and day 16 (B) IFrag/ mice. TRAP-posi-
tive osteoclasts are stained red along the trabec-
ular bone, demonstrating increased osteoclast
numbers along the trabecular bone of infected
compared with uninfected IFrag/ mice.
Also of note is the decreased bone marrow
cellularity in bone marrow space of infected
IFrag/ mice.with inc
counts w
ng infe
TRAP ac
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erosion perimeters per bone perimeter (Figure 3F) only in
infected IFrag/ mice, suggesting accelerated oste-
oclasts activity. Interestingly, osteoblast numbers and
bone perimeter also increased, suggesting an increased,
compensatory activity (Figure 3G).
Femoral bones from four uninfected (day 0) and four
infected (day 16) IFrag/ mice were also analyzed by
microCT51 to further evaluate structural bone changes
following Pneumocystis lung infection. Shown in Figure
4A are three-dimensional images demonstrating trabec-
ular and cortical bone structure of the comparison
groups. Images show an increased transition from plate-
like to rod-like elements characteristic of deterioration of
cancellous bone structure. This transition is defined by a
morphometric parameter called Structure Model Index
(SMI). The SMI value increases from 0 (ideal plate) to 3
(ideal rod) are reflective of these structural changes. The
connectivity density is a measure of the degree to which
Figure 3. Bone histomorphometric analysis reveals loss of trabecular bone
numbers and increased osteoclast activity in IFrag/ mice compared with
RAG/ mice in response to Pneumocystis lung infection. A: von Kossa
staining of calcified, methyl methacrylate embedded bone sections of day 0
and day 16 IFrag/ and RAG/ mice demonstrates mineralized bone. B:
Adjacent bone sections stained with Goldner’s trichrome highlight osteoid
seams and were used to perform the bone histomorphometric analysis.
Original magnification: 40 for all sections; 200 for the overlaid images.
Standard bone histomorphometric analysis was performed at the Center of
Metabolic Bone Diseases, University of Alabama, by the methods of Parfitt et
al49,50 using Bioquant Image Analysis software (R & M Biometrics). Analysis
revealed reduced bone perimeter per tissue area (C) and trabecular bone
numbers per millimeter (D), associated with increased osteoclast numbers
per bone perimeter (E) and increased bone erosion perimeters per millimeter
(F) and increased osteoblast numbers per bone perimeter (G) only in
IFrag/ mice in response to Pneumocystis lung infection. Statistical analysis
was performed using a one-way analysis of variance. Values were compared
to uninfected RAG/ mice and are shown as mean  SEM (n  4). *P 
0.05, **P  0.01, and ***P  0.001.a structure is multiply connected and reflects the integrityof the microstructure of the trabecular bone. Consistent
with our histomorphometric analysis (Figure 3), the SMI
values increased in day 16 IFrag/ mice compared with
day 0 mice (Figure 4B), whereas the connectivity density
decreased (Figure 4C). In addition and consistent with
loss of bone mass, trabecular numbers and bone volume/
tissue volume decreased, whereas trabecular separation
increased in day 16 IFrag/ mice (Figure 4, D-F). Al-
though none of these differences were statistically signif-
icant, likely because of the variability of disease progres-
sion among individual mice (Figure 4A), the trends
support our histomorphometric analysis.
Deviated Bone Marrow Cytokine Profile Caused
by Pneumocystis Lung Infection That Supports
Osteoclastogenesis in IFrag/ but Not
RAG/ Mice
Bone loss in IFrag/ mice is preceded by induction of
bone marrow failure after day 7 of Pneumocystis lung
infection (Figure 5A),43 although Pneumocystis lung bur-
den (Figure 5B) and the extent of lung inflammation,
based on cell numbers in bronchoalveolar lavage, do not
significantly differ between the mouse groups (Figure
5C). However, whether and how bone marrow failure and
bone loss are interconnected in our model are not clear.
Figure 4. MicroCT analysis of IFrag/ femoral bones demonstrate struc-
tural changes of the trabecular bone in response to Pneumocystis lung
infection. A: Three-dimensional images of IFrag/ femoral bones at days 0
and 16. All scanning was conducted on a Scanco microCT 40 scanner and
performed by Scanco. Note the reduction of plate-like elements in the bones
from day 16 mice, also reflected in the increase of the SMI (B). Other
numerical data from this analysis included connectivity density (C), trabec-
ular bone number per millimeter (D), trabecular separation (E), and BV/TV
(F). Statistical analysis was performed using a Mann-Whitney test.
ups. Stat
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are linked, and a distinct set of cytokines mediating in-
flammation is also responsible for promoting osteoclas-
togenesis.52,53 The cytokines involved are TNF-, IL-1,
IL-6, and the myeloid growth factor M-CSF. However, of
specific importance is the osteoclast differentiation factor
RANKL. RANKL itself is negatively regulated by its decoy
receptor OPG.24,25,52 To determine whether any of these
factors were differentially regulated in bone marrow from
IFrag/ versus RAG/ mice in response to Pneumo-
cystis lung infection, bone marrow cells were harvested at
day 0, 7, and 10 after infection, and cytokine analysis of
bone marrow cell lysates was performed (Figure 6). Al-
though there were insufficient IFrag/ bone marrow cell
numbers at day 16 after infection to perform extensive
cytokine analysis, the data obtained between day 0 and
10 are most relevant because they reflect the induction
phase of the condition seen in our system.
The findings revealed that virtually all proinflammatory
cytokines relevant to bone remodeling and osteoclasto-
Figure 5. Bone marrow failure in IFrag/mice is not associated with differ
with RAG/ mice. Tissues were harvested from day 0, 7, 10, and 16 IFrag
RAG/ mice, whereas IFrag/ mice progressed to bone marrow failure at
numbers collected at the same time (C) were not different between the gro
shown are mean  SEM (n  4). **P  0.01, ***P  0.001.
Figure 6. IFrag/ mice develop a deviated bone marrow cytokine respons
Cytokine protein analysis was performed from bone marrow cell lysates at
technique for M-CSF (A), IL-6 (B), IL-1 (C), IL-1 (D), TNF- (E), RANKL (F)
/marrow from IFrag mice consistent with osteoclastogenesis and bone marrow c
variance. Values shown are mean  SEM (n  4). *P  0.05, **P  0.01, and ***P genesis, with the exception of IL-6, were up-regulated in
bone marrow from IFrag/ compared with RAG/mice
in response to Pneumocystis lung infection. Factors in-
volved in promoting preosteoclast differentiation, such as
M-CSF, TNF-, and IL-1 family members, were already
high at day 7 after infection (Figure 6, A-E), whereas
RANKL, the key factor for osteoclast maturation and dif-
ferentiation, was highly induced in day 10 IFrag/ mice
(Figure 6F). Surprisingly, at the same time, its decoy
receptor OPG was also significantly induced in bone
marrow from day 10 IFrag/ mice (Figure 6G).
Although capable of neutralizing RANKL actions,54
OPG can also act as a decoy receptor for the proapop-
totic cytokine TRAIL.55 Because bone marrow cell apop-
tosis was a prominent presenting symptom in our infec-
tion model,43 we also measured TRAIL levels in the same
bone marrow cell lysates. Interestingly, TRAIL expression
was already significantly up-regulated in day 7 IFrag/
mice (Figure 6H) and thus preceded the induction of
RANKL andOPG. The cytokine levels presented in Figure 6
Pneumocystis lung burden and extent of lung inflammation when compared
RAG/ mice. A: Bone marrow counts demonstrated stable cell numbers in
ter infection. Pneumocystis lung burden (B) and bronchoalveolar lavage cell
istical analysis was performed using a two-way analysis of variance. Values
ting osteoclastogenesis, suggesting an unbalanced RANKL/OPG/TRAIL axis.
, and 10 after Pneumocystis lung infection using an ELISA-based multiplex
), and TRAIL (H). Results demonstrate a deviated cytokine response in boneences in
/ and
day 7 afe promo
day 0, 7
, OPG (Gell apoptosis. Statistical analysis was performed using a two-way analysis of
0.001.
158 Wilkison et al
AJP July 2012, Vol. 181, No. 1are also summarized in Supplemental Table S1 (available
at http://ajp.amjpathol.org) as fold change IFrag/ rela-
tive to RAG/.
Inhibition of Bone Loss After Pneumocystis
Lung Infection and Protection of HPC Viability
by Bisphosphonate Treatment of IFrag/ Mice
To address whether the loss of bone structure in IFrag/
mice was causally linked to bone marrow failure, we
treated Pneumocystis infected IFrag/ mice with rise-
dronate, a bisphosphonate that inhibits osteoclasts.44
The effects on bone structure, bone marrow cell numbers,
and HPC activity were measured at day 16 after infection.
As demonstrated in von Kossa stains (Figure 7A), risedro-
nate treatment had a visual effect on the extent of miner-
alized bone in IFrag/ mice, and bone histomorphomet-
ric analysis revealed that trabecular bone numbers per
millimeter increased greatly compared with untreated
mice (Figure 7B). Total bone marrow cell numbers of
treated and untreated day 16 IFrag/ mice, however,
revealed low counts relative to uninfected mice in both
groups (Figure 1A and Figure 5A), indicating progression
of bone marrow failure (Figure 7C). Surprisingly, the he-
matopoietic CFC assay found significantly more colony
formation with bone marrow cells from risedronate-
treated mice compared with nontreated mice. This find-
ing indicates more viable HPCs in bone marrow from day
16 IFrag/ mice, in which bone loss was inhibited by
risedronate treatment (Figure 7D). These data suggest apartial connection between bone loss and bone marrow
failure.
Amelioration of Progression of Bone Marrow
Failure by Treatment of IFrag/ Mice with
Neutralizing Anti-TRAIL Antibody After
Pneumocystis Lung Infection
We recently determined that increased reactive oxygen
species, possibly due to reduced growth factor produc-
tion, and increased TNF- in bone marrow of IFrag/
mice during Pneumocystis lung infection are partially re-
sponsible for the progression of bone marrow failure in
our model.43 To determine whether increased TRAIL pro-
duction in bone marrow of IFrag/mice also contributed
to the phenotype, we treated IFrag/ mice with neutral-
izing TRAIL antibody (750 g of N2B2 three times
weekly) during infection. This approach reduced TRAIL
concentrations in the bone marrow by approximately
50% (data not shown). Under this treatment regimen,
progression of bone marrow failure was ameliorated at
day 10 after infection (Figure 8) but subsequently contin-
ued to progress (data not shown). These data support a
partial role of TRAIL in the pathogenesis of bone marrow
failure in our system.
Discussion
We found that the absence of type 1 IFN signaling during
systemic stress responses to Pneumocystis lung infection
ure 7. Bisphosphonate treatment of Pneumocystis-infected IFrag/
ce prevents bone loss and maintains HPC activity but does not protect
m mature bone marrow cell loss. Two groups of IFrag/ mice were
ected with Pneumocystis, with one group receiving the osteoclast
ibitor risedronate during the infection. Mice were harvested at day
after infection. A: von Kossa stains of calcified bone sections from
resentative IFrag/ mice of each group. B: Trabecular bone num-
rs were assessed by bone histomorphometric analysis, which re-
aled increased numbers in treated day 16 IFrag/ mice. C: Total
ne marrow cell counts at day 16 do not differ between the groups. D:
C viability, assessed by CFC assays, is significantly higher in bone
rrow cells from risedronate-treated compared with untreated day 16
ag/ mice. Statistical analysis was performed using a Mann-Whit-
y two-tailed test. *P  0.05, ***P  0.001.Fig
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osteoclastogenesis and induces significant bone loss.
Osteoclasts are cells of myeloid origin that are
uniquely capable of rapidly resorbing bone and are con-
sidered an innate immune cell of the bone.56 Soluble
TRAP assays from bone marrow cell lysates during Pneu-
mocystis infection indicated increased differentiation of
preosteoclasts from myeloid precursor cells after the
early systemic response, specifically in IFrag/ but not
RAG/ mice. Comparative bone histomorphometric
studies confirmed increased osteoclast numbers along
the trabecular bone and loss of trabecular bone numbers
exclusively in IFrag/ mice in response to Pneumocystis
infection. Osteoblast numbers in infected IFrag/ mice
were also increased, possibly as a compensatory effect,
and make a defect of these bone-producing cells unlikely
the cause of the rapidly progressing bone loss observed
in our model.57 Type 1 IFNs are known to negatively
regulate osteoclastogenesis,58 although our model also
reveals that the systemic response to the focal Pneumo-
cystis lung infection seems to accelerate osteoclastogen-
esis in the absence of type 1 IFN signaling. This finding
suggests a unique role of type 1 IFNs specifically in the
modulation of the systemic responses to Pneumocystis
lung infection.
Low-grade Pneumocystis infection is common in HIV-
positive patients, even those undergoing HAART, in
which the type 1 IFN system may still be impaired.39
Pneumocystis colonization has also been detected in
lungs from non-AIDS patients with COPD and is linked to
exacerbation of the disease.59,60 Interestingly, COPD is
often treated with glucocorticoids, which impair the type
1 IFN system by the nature of their action.41 Both HIV
infection and COPD are associated with osteoporosis,
and patients with either disease may also have blood
abnormalities.6,61,62 Although mechanisms are not
clearly understood, a deviated systemic immune re-
sponse is thought to be involved.61 Therefore, the impli-
cation that a deviated systemic inflammatory response to
Figure 8. Neutralization of TRAIL ameliorates progression of bone marrow
failure in response to Pneumocystis lung infection. Two groups of IFrag/
mice were infected with Pneumocystis. One group was also intraperitoneally
administered anti-TRAIL antibody (clone N2B2) at 750 g three times per
week throughout the infection and starting 1 day before infection. Total bone
marrow cell counts at day 10 after infection. *P  0.05.Pneumocystis lung infection, possibly due to impairedtype 1 IFN signaling, could be causally linked to accel-
erated osteoporosis is intriguing.
Cytokines are important communicators of inflamma-
tion, and osteoclastogenesis and inflammation are tightly
linked.53 Further analysis indeed revealed a deviated
cytokine profile, supporting osteoclastogenesis uniquely
present in the bone marrow of day 7 and 10 IFrag/ but
not RAG/ mice. M-CSF supports the differentiation of
myeloid precursors toward the macrophage lineage and
preosteoclasts63 and was also up-regulated by day 7
after infection in bone marrow from IFrag/ mice. This
finding was consistent with increased TRAP activity in
bone marrow cell lysates by day 10. TNF- and IL-1
cytokines were also up-regulated in day 7 and day 10
IFrag/ mice but not in RAG/ mice. Both cytokines
are known to initiate RANKL production, a key osteoclast
maturation factor.64 RANKL was indeed up-regulated in
bone marrow from day 10 IFrag/ mice, which was
followed by subsequent maturation and activity of oste-
oclasts along the trabecular bone in day 16 IFrag/
mice. The early deviation toward increased IL-1 and
TNF- production in bone marrow from IFrag/ and not
RAG/ mice is striking. Although type 1 IFNs are pri-
marily considered a proinflammatory cytokine,9 more re-
cent research clearly identified their importance in im-
mune modulation and down-regulation of inflammation. In
this regard, type 1 IFNs have been shown to induce IL-10
production via STAT-1–mediated pathways65 and also
directly suppress TNF- gene transcription via the induc-
tion of TWIST transcriptional repressors.66 Furthermore,
they interfere with IL-1 maturation by repressing the
activity of NLRP1 and NLRP3 inflammasomes.67 The pro-
found deviation of the cytokine profile in bone marrow
from IFrag/ compared with RAG/ mice stresses the
importance of type 1 IFNs in the regulation of the sys-
temic response to Pneumocystis lung infection and how it
may affect tissue homeostasis at distant organ sites.
Type 1 IFNs are known to negatively regulate oste-
oclast maturation via direct interference in the RANKL/
RANK-signaling pathway by blocking c-FOS protein syn-
thesis and thus disrupting further differentiation signals.68
This interference would be consistent with the phenotype
of osteoporosis in our model, except that uninfected
IFrag/ mice did not seem to have significantly accel-
erated bone loss when compared with uninfected
RAG/ mice, and the differences between the groups
evolved in response to Pneumocystis lung infection. Sur-
prisingly, protein levels for the RANKL decoy receptor
OPG were also greatly induced in bone marrow from
IFrag/ but not in RAG/ mice in response to Pneumo-
cystis lung infection. High OPG levels should be able to
interfere with RANKL/RANK interaction on preosteoclasts
and impede their differentiation, independent of the in-
hibitory effects of type 1 IFN-mediated signals.48 How-
ever, OPG also functions as a decoy receptor for the
proapoptotic cytokine TRAIL,55 which is considered a
regulator of bone marrow cell homeostasis by also
inducing apoptosis in senescent neutrophils.69 Fur-
thermore, sensitivity to TRAIL-mediated cytotoxicity
may increase under pathologic conditions.55,69,70
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itantly in our model in response to Pneumocystis lung
infection, and an imbalance among RANKL, OPG, and
TRAIL may be linked to these phenotypes. Indeed, TRAIL
protein concentrations, in conjunction with TNF- and
IL-1, were elevated only in bone marrow from IFrag/
mice starting at day 7 after infection and thus preceded
both bone marrow failure and accelerated bone loss.
These data imply that type 1 IFN signaling may negatively
regulate not only TNF- and IL-1 but also TRAIL.
Bone marrow failure in IFrag/ mice is associated
with loss of precursor cell activity and numbers.43 The
HSC resides in a protected niche along the trabecular
bone, and loss of bone structure is associated with loss of
HSC numbers.71 This finding raised the question of what
extent the evolving bone loss itself may contribute to
bone marrow failure in IFrag/ mice after Pneumocystis
lung infection. Bisphosphonate treatment effectively in-
hibited osteoclast activity and increased trabecular bone
numbers and volume of IFrag/ mice during Pneumo-
cystis lung infection compared with untreated, infected
mice. However, the visual effect on bone marrow failure
progression was minimal because total bone marrow cell
numbers still rapidly decreased. Nevertheless, although
band neutrophils and myelocytes disappeared from the
marrow space (data not shown), the HPC activity (mea-
sured by CFC assays) was significantly improved in
treated compared with untreated day 16 IFrag/ mice,
suggesting a protective role of bone with regard to early
progenitor cell viability. Interestingly, we previously dem-
onstrated that treatment of IFrag/ mice with an anti-
TNF- antibody during infection had no effect on neutro-
phil numbers but improved precursor cell activity.43
Given the supportive role of TNF- in osteoclast matura-
tion, the mechanisms underlying the partial effect of TNF
blockage on improved HPC activity may potentially be
due to effects on bone metabolism rather than inhibition
of apoptotic effects of TNF-. The loss of more mature
bone marrow cells may be due to an additional lack of
growth factors, as previously reported,43 and apoptotic
activity of other mediators, such as TRAIL. Experiments
aiming to block TRAIL activity in vivo using neutralizing
antibody treatment also showed only a partial effect on
the progression of bone marrow failure, supporting the
notion of a multifactorial pathogenesis. However, assays
performed to determine the TRAIL neutralization efficiency
within the bone marrow, using ELISA with DR5-TRAIL re-
ceptor as a capture reagent, revealed only partial neutral-
ization, with concentrations well above baseline levels
(data not shown). Therefore, other means to more effi-
ciently block TRAIL activity (eg, TRAIL receptor blocking
antibodies or OPG administration) are needed to further
assess the exact role of TRAIL in bone marrow failure and
bone loss in our model.
Together these data demonstrate that type 1 IFN sig-
naling regulates multiple aspects of the systemic re-
sponse to Pneumocystis lung infection, including bone
marrow homeostasis and bone metabolism possibly in-
volving direct regulation the RANKL/OPG/TRAIL axis in
our mouse model of disease. A defect in type 1 IFN
signaling and low-grade Pneumocystis lung infection arecommon in patients with HIV (undergoing HAART) and
those with chronic lung disease undergoing corticoste-
roid treatment. Whether a deviated systemic immune re-
sponse to Pneumocystis lung infection or colonization
due to impaired type 1 IFN signaling could also acceler-
ate osteoporosis in humans, and thus affect bone marrow
functions, is worth investigating. Such a study could have
implications for prevention and treatment strategies.
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